US 7,544,171 · Application 11/238,499 · Granted Jun 9, 2009
US 7,544,171
Methods for promoting nerve regeneration and neuronal growth and elongation
Estimated expiration
November 5, 2025
Expired 343 days ago
Earliest effective filing
Mar 4, 2005
+ 20 years
Mar 4, 2025
PTA +255d
Nov 14, 2025
TD cap (US 7,470,240)
Nov 5, 2025
Final
Nov 5, 2025
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).
Calculation details
Base term
- Filing date
- September 29, 2005
- Earliest effective filing
- March 4, 2005
- Issue date
- June 9, 2009
- PTA
- +255 days
- Base expiry (before PTA)
- March 4, 2025
March 4, 2005 + 20 years = March 4, 2025 + 255 PTA days = November 14, 2025
- Continuation-in-part of application 11/122,154, filed May 4, 2005, issued as US 7,470,240
- Continuation-in-part of application 11/071,156, filed Mar 4, 2005
- Continuation-in-part of application 11/071,156, filed Mar 4, 2005
- PRO60/621,028 — Provisional — not used for base term
- PRO60/642,149 — Provisional — not used for base term
- PRO60/621,028 — Provisional — not used for base term
- PRO60/642,149 — Provisional — not used for base term
- PRO60/699,719 — Provisional — not used for base term
- PRO60/621,028 — Provisional — not used for base term
- PRO60/642,149 — Provisional — not used for base term
Terminal disclaimers
TD caps expiration to November 5, 2025 (earliest expiring referenced patent: US 7,470,240)
US 7,470,240· Application 11/122,154Capping patent
Pressure pulse/shock wave therapy methods and an apparatus for conducting the therapeutic methods
- Filing date
- May 4, 2005
- Earliest effective filing
- Mar 4, 2005
- Issue date
- Dec 30, 2008
- PTA
- +246 days
- Calculated expiration
- Nov 5, 2025
Continuation-in-part of 11/071,156, filed Mar 4, 2005
Mar 4, 2005 + 20y + 246d PTA = Nov 5, 2025
US 9,653,143· Application 15/170,785
Apparatuses including memory section control circuits with global drivers
- Filing date
- Jun 1, 2016
- Earliest effective filing
- Aug 24, 2011
- Issue date
- May 16, 2017
- PTA
- 0 days
- Calculated expiration
- Aug 24, 2031
Continuation of 14/505,717, filed Oct 3, 2014, issued as US 9,368,184
Continuation of 14/084,417, filed Nov 19, 2013, issued as US 8,861,296
Continuation of 13/217,070, filed Aug 24, 2011, issued as US 8,588,022
Continuation of 13/217,070, filed Aug 24, 2011, issued as US 8,588,022
Continuation of 14/084,417, filed Nov 19, 2013, issued as US 8,861,296
Continuation of 13/217,070, filed Aug 24, 2011, issued as US 8,588,022
Aug 24, 2011 + 20y = Aug 24, 2031
US 7,544,171· Application 11/238,499(from application 11/238,499)
Methods for promoting nerve regeneration and neuronal growth and elongation
- Filing date
- Sep 29, 2005
- Earliest effective filing
- Mar 4, 2005
- Issue date
- Jun 9, 2009
- PTA
- +255 days
- Calculated expiration
- Nov 14, 2025
Continuation-in-part of 11/122,154, filed May 4, 2005, issued as US 7,470,240
Continuation-in-part of 11/071,156, filed Mar 4, 2005
Continuation-in-part of 11/071,156, filed Mar 4, 2005
Mar 4, 2005 + 20y + 255d PTA = Nov 14, 2025
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
The prosecution record for your AI
Application 11/238,499 · US 7,544,171
You have the date. Your AI can have the file.
PatentReply compiles the prosecution history behind US 7,544,171: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One new public application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US7544171Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.